Renal Cell Carcinoma

Molecular Features and Treatment Updates

  • Mototsugu Oya

Table of contents

  1. Front Matter
    Pages i-x
  2. Xifeng Wu, Xiang Shu
    Pages 1-18
  3. Masaya Baba, Laura S. Schmidt, W. Marston Linehan
    Pages 19-82
  4. Tomoya Fukawa, Nicholas Shannon, Dachuan Huang, Jing Tan, Xiaosai Yao, Steven G. Rozen et al.
    Pages 83-103
  5. Shuji Mikami, Naoto Kuroda, Yoji Nagashima
    Pages 105-137
  6. Tsunenori Kondo
    Pages 177-207
  7. Jaimin R. Bhatt, Patrick O. Richard, Michael A. S. Jewett
    Pages 209-220
  8. Dae Y. Kim, Jose A. Karam, Christopher G. Wood
    Pages 221-235
  9. José Manuel Ruiz Morales, Daniel Y. C. Heng
    Pages 237-251
  10. Christos E. Kyriakopoulos, Brian I. Rini
    Pages 253-272
  11. Camillo Porta, Silvia Chiellino, Mimma Rizzo
    Pages 273-294
  12. Shigehisa Kitano, Ayumu Ito, Youngji Kim
    Pages 295-317
  13. Mototsugu Oya, Toshiaki Shinojima, Ryuichi Mizuno
    Pages 351-367

About this book

Introduction

This book provides a comprehensive review of diagnosis and treatments of renal cell carcinoma (RCC) for practitioners and researchers with an interest in this disease. A major aim of the book is to present the most important and most recent advances in molecular bases and targeted therapy for this neoplasm. The remarkable resistance to chemotherapy and radiotherapy and the minimum contribution of cancer genes that commonly mutate in other adult epithelial cancers have made RCC highly distinct from other types of solid neoplasms. In the past decade, however, treatment options for RCC have been expanding and moving quickly toward laboratory-based and molecular-targeted therapies. Advances in RCC therapy also have brought novel treatment options to other types of cancer, such as a TKI for hepatocellular carcinoma and gastrointestinal tumors, as well as mTOR inhibitors to progressive neuroendocrine tumors of pancreatic origin and to breast cancer, suggesting that RCC is no longer an "orphan disease" in the field of molecular oncology. Additional topics covered in the book include pharmacokinetics and pharmacodynamics in molecular-targeted agents and the putative mechanism of resistance to anti-angiogenic agents, such as intratumoral heterogeneity or cancer stem cell population. This volume provides the latest and most useful information for all readers who are eagerly devoted to curing renal cell carcinoma.

Keywords

Molecular-targeted therapy TKI anti-angiogenic agent mTOR inhibitors tyrosine-kinase inhibitors

Editors and affiliations

  • Mototsugu Oya
    • 1
  1. 1.Department of UrologyKeio University School of MedicineTokyoJapan

Bibliographic information

  • DOI https://doi.org/10.1007/978-4-431-55531-5
  • Copyright Information Springer Japan KK 2017
  • Publisher Name Springer, Tokyo
  • eBook Packages Medicine
  • Print ISBN 978-4-431-55530-8
  • Online ISBN 978-4-431-55531-5
  • About this book